Noor Ul Ain Rehman
2 min read
In This Article:
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company’s VAFSEO product and its potential in the CKD anemia market.
VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO’s ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia.
A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics.
The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions.
Caufield pointed out VAFSEO’s oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases.
While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Debt Free IT Penny Stocks To Buy and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
